×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Kelly Irvin
No matter how cancer makes you look, you’re still you—a better you.
 
Oliver Dorigo, M.D., Ph.D.

Oliver Dorigo, M.D., Ph.D., associate professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses the lack of effective screening methods for ovarian cancer.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.
 
Jason M. Broderick
A supplemental new drug application (sNDA) for Rubraca (rucaparib), a PARP inhibitor, has been granted a priority review by the Food and Drug Administration.

 
Jason Harris
Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.
Tony Hagen
As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.
Anya Khomenko

When facing ovarian cancer, it is critical to stay healthy and well-informed, says Anya Khomenko.
Angelica Welch
Checkpoint inhibitors in combination with PARP inhibitors are garnering interest, with the impact of PARP inhibitors already well established in this tumor type.
Bright Pink
For some, being home for the holidays means lots of extra family time. Bright Pink, a national nonprofit focused on the prevention and early detection of breast and ovarian cancer, shares how women can take advantage of this opportunity to enrich their knowledge about their family's health history.
 
Katie Kosko
A newly studied blood test could be the answer to a serious question: How can a woman tell if she has ovarian cancer in its earliest stage?
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable